GLP-1 Non-Responders: Why Ozempic or Mounjaro Doesn’t Work for Everyone (and What to Do Next)

Written by Dan Cripe, RN, BSN & Marcia Cripe, RN | Last Updated: September 18, 2026

You can be several weeks into a GLP-1 prescription and still find yourself wondering whether you’re getting the same medication everyone else is talking about. They describe quieter hunger, smaller portions, and steady weight loss. You’re looking at a nearly unchanged scale—or dealing with nausea—and wondering what you’re missing.

Some people do have an inadequate response to a particular medication. But before deciding that’s what is happening to you, it matters whether you’ve felt little change, noticed appetite changes without much weight loss, struggled to tolerate treatment, or stopped losing after earlier success. Those experiences can look similar on the scale while pointing toward different next steps.

The goal is to understand what your treatment has actually done, whether it has had a reasonable opportunity to help, and what deserves another look. You should not have to choose between blaming yourself and being told to wait indefinitely.

What Does “Non-Responder” Actually Mean?

When you hear “non-responder,” it can sound like a permanent label: this medication works for other people, but your body simply doesn’t respond. In research, the term is usually much narrower. It describes whether someone reached a defined result by a particular point in a study.

For weight loss, a commonly reported threshold is at least 5% of starting body weight. If you started at 200 pounds, that would mean losing 10 pounds. Someone who lost 8 pounds would fall below that threshold, even though they had lost weight.

That distinction matters because “below 5%” does not tell us why the result occurred. It does not separate someone who took treatment consistently but had little benefit from someone whose treatment was interrupted or limited by side effects. The threshold measures an outcome; it is not a complete explanation.

There also is no single definition that applies to every medication, treatment goal, and timeline. If your blood glucose improves substantially but your weight changes little, your medication may be helping your diabetes without adequately meeting your weight-management goals. Both observations belong in the assessment. 

A more useful starting question is: “Am I getting enough benefit from this treatment for the reason I’m taking it?”

Four Situations That Can Feel Like the Medication Isn’t Working

1. You feel almost nothing

You take your injection, wait for something to change, and continue getting hungry at the usual times. You may still enjoy the same foods and finish similar portions. Without a noticeable shift, it is understandable to wonder whether anything is happening.

The first thing to establish is where you are in treatment. Starting doses introduce the medication gradually; they do not necessarily show you what an appropriate maintenance regimen will do. Zepbound’s 2.5 mg dose, for example, is an initiation dose rather than an approved maintenance dose. Injectable Wegovy also begins with gradual escalation. 

Your appetite observations are useful, but they need to sit alongside your weight trend and, when relevant, glucose readings. “I don’t feel different yet” and “there has been no measurable benefit after an appropriate treatment trial” are different conclusions.

2. You’re eating less but losing little weight

This can be especially confusing because you have noticed a change. You leave food on your plate or feel satisfied sooner, yet the scale barely moves.

Appetite and weight are connected, but they are not interchangeable measurements. Feeling fuller sooner tells you something about your eating experience. Your weight trend reflects what is happening over time. A smaller dinner may be meaningful, but it does not describe the whole day’s intake or explain every short-term change on the scale.

A useful assessment looks at the overall pattern without assuming that you are doing something wrong. Bowel contents and fluid changes can complicate short-term readings, but they should not become the explanation offered month after month. If appetite has changed and weight progress remains limited, that is a specific problem to investigate—not a contradiction you have to resolve yourself.

3. Side effects prevent you from tolerating treatment

Perhaps the medication does affect you, but the effect is mostly unpleasant. Each increase brings nausea, vomiting, or difficulty eating, and you cannot comfortably remain on the planned regimen.

That situation needs to be recognized as a tolerability problem. You may not have been able to receive enough sustained treatment to judge its potential benefit. At the same time, a medication that you cannot tolerate may not be a workable treatment for you, regardless of its trial results.

Wegovy labeling allows delayed escalation when a dose is not tolerated, and Zepbound maintenance-dose selection considers both response and tolerability. Those are reasons to reassess the plan rather than treating the dosing calendar as something you must push through. 

4. You lost weight, then reached a plateau

If you lost 30 pounds and have maintained that loss, you have already had a weight response. A plateau does not erase it.

The question has changed from “Does this treatment help me lose weight?” to “Is the result I’ve reached sufficient, and what should happen now?” Maintaining a meaningful loss and continuing to lose are different outcomes, even though only one makes the scale move downward.

Plateaus occurred in tirzepatide research among people who had achieved clinically meaningful weight loss. That helps explain why leveling off is not automatically evidence of treatment failure. A few flat readings need context; a persistent plateau or regain deserves a review of the longer trend and your remaining goals. 

What Do the Semaglutide, Tirzepatide, and Retatrutide Trials Show?

Once you’ve separated those situations, the next question is reasonable: even with treatment, do some people fail to lose much weight?

Yes. The major trials show substantial average losses, but they also show that not everyone reaches the same result. Looking at how many participants reached at least 5% weight loss makes that variation easier to see.

The following are selected published results in adults with overweight or obesity without diabetes. “Below 5%” is calculated by subtracting the reported response percentage from 100%.

These percentages come from separate studies and retain the rounding used in their reports. They are not a head-to-head comparison. 

The findings give you a reason to take inadequate response seriously. They do not establish that 13.6% of all people are biologically incapable of responding to semaglutide, or that everyone will respond to retatrutide.

Who was counted matters. The semaglutide percentage shown here describes participants with available measurements at week 68. The other studies used their specified analysis approaches, and the trials differed in duration, size, and handling of treatment discontinuation and missing information. These are outcomes under particular study conditions—not permanent response rates attached to each drug.

Does Retatrutide Really Have Zero Non-Responders?

The striking finding is real, but its boundaries matter: the phase 2 study reported a 100% rate of at least 5% weight loss in the 8 mg and 12 mg groups at 48 weeks. The 4 mg group’s result was 92%. 

Reaching 5% is also different from reaching your personal goal. For someone starting at 250 pounds, that threshold is 12.5 pounds. A study can report that everyone in a particular analysis reached that threshold without showing that everyone lost the amount they hoped to lose.

Retatrutide has since progressed to phase 3 results. Lilly’s TRIUMPH-1 report described average loss of 28.3% at 80 weeks with 12 mg in its efficacy analysis; an analysis accounting for treatment discontinuation reported 25.0%. Those averages are promising, but neither establishes a universal zero non-response rate. 

As of this article’s September 30, 2026 review, retatrutide remained investigational. Its findings help describe where treatment research is heading, rather than an approved medication change readers can currently make. 

Are Newer Treatments Getting Better?

There is meaningful progress in what these treatments can achieve. There is also a difference between saying that research is improving our options and saying that each newer medication will work better for every person.

Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at GIP and GLP-1 receptors, and retatrutide is being studied for activity at GIP, GLP-1, and glucagon receptors. Those differences help explain why researchers are studying different treatment effects, but the number of receptor targets alone cannot tell you which treatment will suit you best.

For semaglutide and tirzepatide, there is a direct comparison. In SURMOUNT-5, average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide, using maximum tolerated tirzepatide doses of 10 or 15 mg and semaglutide doses of 1.7 or 2.4 mg. That establishes a difference between the regimens studied, not every possible dose or individual outcome. 

For you, the encouraging part is that one disappointing treatment experience does not exhaust the available possibilities. The next choice still needs to account for your health, tolerability, access, and goals.

Is It Too Early to Judge Your Response?

You might tell your prescriber, “I’ve been taking this for three months.” But those three months could include several weeks at a starting dose, a pharmacy delay, and an increase postponed because of nausea.

That history gives a different picture from three uninterrupted months at a maintenance dose. Both timelines matter: how long you’ve been trying treatment, and how much consistent treatment you’ve actually received.

A later analysis of SURMOUNT-1 illustrates why early results are not always the final result. Among 278 participants who had lost less than 5% at week 12, 70% reached at least 5% by week 24 and 90% by week 72. This analysis included participants who received at least 75% of assigned doses and had measurements at the required visits, so its findings do not describe everyone who started treatment. 

The practical answer is to replace an indefinite “give it time” with a specific plan: what dose and duration are being assessed, what benefit you are looking for, and when you will review the result.

Related Clinical Protocol
If you’re unsure where you are in treatment, understanding the difference between GLP-1 starting, intermediate, and maintenance doses⁠ can help you prepare for that discussion.

Before Calling It Non-Response, Check the Treatment Itself

A medication can only be fairly assessed if you understand what treatment you have actually received. Reviewing the practical details can uncover a correctable problem without assuming that you made a mistake.

Bring the prescription and delivery instructions into the conversation, especially if you are uncertain about:

• Your dose: The exact product, formulation, prescribed amount, and time spent at each dose.
• Administration: Whether you are using your particular pen, vial, syringe, or oral medication correctly.
• Interruptions: Missed doses, supply gaps, restarts, or symptoms that delayed treatment.
• Storage: Any temperature exposure or handling question that needs the dispensing pharmacist’s review.

The purpose is to establish a reliable starting point for the next decision. If something is unclear, have it checked before changing the amount yourself. Increasing early, combining GLP-1 medications, or experimenting with syringe markings can create risk without resolving why the original plan was not helping enough. 

What Else Could Be Affecting Your Results?

An assessment should look beyond the prescription. Other medications, health conditions, eating patterns, activity, sleep, and access barriers can all be relevant. Current obesity guidance includes these areas in an individualized treatment evaluation. 

The useful question is not “What else can we blame?” It is “Is there something here that changes the plan?” For example, reviewing a medication that can promote weight gain raises a different question from discovering that nausea has repeatedly interrupted treatment. Each finding needs its own response.

That does not mean you automatically need an extensive hormone panel or a rigid tracking routine. Testing and support should address plausible concerns in your history. If eating patterns need reviewing, the discussion should help you understand the pattern and make a workable adjustment.

If you are barely eating, becoming progressively weaker, or struggling to drink, say so plainly. Those details need attention even if weight loss remains disappointing. Inability to keep fluids down, significant dehydration, or severe or persistent abdominal pain calls for prompt medical assessment rather than further dietary restriction. 

When Is It Time to Reassess the Plan?

You do not have to wait until a medication has definitively “failed” to discuss whether it is helping enough. Follow-up is where the plan should be evaluated while treatment is happening.

ADA guidance describes less than 5% weight loss after three months as modest early weight loss, then considers glucose response, tolerability, alternatives, and treatment burden when evaluating continuation. It does not reduce that decision to the scale alone. 

The timeline also depends on the medication and setting. UK NICE guidance, for example, considers whether to continue tirzepatide when less than 5% has been lost after six months on the highest tolerated dose, taking benefits and risks into account. That is not a universal US stopping rule; it illustrates why a deadline without its context can mislead. 

A useful reassessment should leave you understanding why the next step is to continue, adjust, or change treatment. Cost belongs in that conversation too. A small benefit may look different to someone paying a substantial amount each month or dealing with persistent side effects.

Could a Different Medication Work If This One Doesn’t?

It may. A limited response to one medication does not establish that another will fail. But the reason for considering a change matters.

Someone who cannot tolerate the current regimen needs a discussion about tolerability as well as effectiveness. Someone who has had little benefit despite consistent treatment needs a discussion about whether a different approach is more likely to meet their goals. Those are more useful conversations than simply asking which medication is strongest.

There is research showing additional benefit after switching. In a prospective study, people with type 2 diabetes who moved from established GLP-1 treatment to tirzepatide had further weight reduction and improved glucose outcomes over 12 weeks. However, they were not specifically an obesity non-responder population, so the study does not establish a guaranteed solution for people who failed another medication. 

Depending on the assessment, options may include adjusting an approved regimen, changing medication, adding appropriate support, or considering other obesity treatments, including metabolic surgery when indicated. The choice should come with a clear goal and a follow-up plan. 

What to Bring to Your Follow-Up Appointment

You do not need to arrive with a perfect spreadsheet. A few concrete details can make the conversation much more useful than “I don’t think it’s working”:

• Your medication, prescribed dose, start date, and approximate time at each dose.
• Your starting weight and recent trend.
• What has changed in hunger, fullness, eating patterns, and relevant glucose readings.
• Side effects, interruptions, and trouble obtaining or affording treatment.
• The result you hoped for and what would make continuing worthwhile.

A useful way to begin is: “Here is what has changed, here is what hasn’t, and here is what I’m finding difficult. What should we assess before deciding the next step?”

Before you leave, ask when you will reassess and what would prompt a change. That gives you something more concrete than another month of wondering.

A Limited Response Deserves a Better Explanation Than “Try Harder”

Some people do not achieve enough weight loss with a particular medication. Others respond later, cannot tolerate an effective regimen, or reach a plateau after meaningful success. Understanding which situation you are in makes it possible to ask a better question about what comes next.

You do not have to interpret a disappointing result as a judgment about your effort. You also do not have to stay indefinitely with a plan that is not meeting your needs. You deserve an explanation of what the treatment has achieved, what may be limiting it, and what options remain.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
   https://doi.org/10.1056/NEJMoa2032183
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
   https://doi.org/10.1056/NEJMoa2206038
3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023.
   https://doi.org/10.1056/NEJMoa2301972
4. American Diabetes Association. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026.
   https://diabetesjournals.org/care/article/49/Supplement_1/S166/163915/8-Obesity-and-Weight-Management-for-the-Prevention
5. Eli Lilly and Company. Zepbound Prescribing Information.
   https://pi.lilly.com/us/zepbound-uspi.pdf
6. Novo Nordisk. Wegovy Prescribing Information.
   https://www.novo-pi.com/wegovy.pdf
7. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. 2025.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC12096058/
8. Eli Lilly and Company. TRIUMPH-1 phase 3 topline results. May 21, 2026. Sponsor report.
   https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
9. Eli Lilly and Company. TRIUMPH-2 detailed results and investigational status. September 29, 2026. Sponsor report.
   https://investor.lilly.com/node/54981
10. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025.
    https://doi.org/10.1056/NEJMoa2416394
11. Ard J, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1. 2025.
    https://pubmed.ncbi.nlm.nih.gov/40677091/
12. American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. 2026.
    https://diabetesjournals.org/docm-care/article/1/1/5/164233/Pharmacologic-Treatment-of-Obesity-in-Adults
13. NICE. Overweight and obesity management: Medicines and surgery.
    https://www.nice.org.uk/guidance/NG246/chapter/medicines-and-surgery
14. Jabbour S, et al. Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. 2024.
    https://pubmed.ncbi.nlm.nih.gov/38723893/